Charmacy Pharmaceutical Co., Ltd. (HKG:2289)

Charmacy Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	530.1	753.6	563.15	634.2	492.67	630.17
Short-Term Investments	10.98	11.05	10.7	10.56	11.13	11.59
Cash & Short-Term Investments	541.08	764.65	573.86	644.76	503.81	641.76
Cash Growth	3.82%	33.25%	-11.00%	27.98%	-21.50%	6.60%
Accounts Receivable	1,518	1,261	1,226	965.35	865.26	731.26
Other Receivables	66	50.02	43.12	41.49	116.91	42.8
Receivables	1,584	1,311	1,270	1,007	982.17	774.06
Inventory	902.28	796.25	655.91	775.84	586.85	509.16
Prepaid Expenses	-	-	1.84	-	-	-
Other Current Assets	517.36	688.95	528.84	384.56	389.53	313.25
Total Current Assets	3,544	3,561	3,030	2,812	2,462	2,238
Property, Plant & Equipment	282.69	294.57	317.6	328.55	294.08	348.44
Goodwill	6	6	6	6.02	6.02	6.02
Other Intangible Assets	66.23	68.33	72.49	76.72	80.86	143.03
Long-Term Deferred Tax Assets	12.74	11.48	7.64	7.38	6.8	8.16
Long-Term Deferred Charges	16.49	18.69	22.91	16.98	16.34	19.21
Total Assets	3,929	3,960	3,457	3,248	2,866	2,763

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1,294	894.06	826.51	936.49	876.78	809.77
Accrued Expenses	67.69	66.98	61.29	58.35	86.48	47.84
Short-Term Debt	1,373	1,762	1,350	1,338	1,166	1,193
Current Portion of Long-Term Debt	4.28	4.25	1.22	-	-	31.78
Current Portion of Leases	9.24	8.97	8.78	6.59	4.15	2.97
Finance Div. Other Current Liabilities	-	0.23	0.2	-	-	-
Current Income Taxes Payable	10.12	14.2	11.72	12.85	27.05	6.41
Current Unearned Revenue	4.77	5.02	2.1	19.49	13.53	46.66
Other Current Liabilities	502.91	525.65	526.3	247.55	81.98	20.44
Total Current Liabilities	3,266	3,281	2,789	2,619	2,256	2,159
Long-Term Debt	36	38.1	13.8	-	-	86.87
Long-Term Leases	19.5	24.21	35.17	30.39	15.75	12.49
Long-Term Unearned Revenue	-	-	-	-	-	0.3
Long-Term Deferred Tax Liabilities	0.41	0.19	0.38	0.6	0.06	0.4
Total Liabilities	3,322	3,344	2,838	2,650	2,271	2,259

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	108	108	108	108	108	108
Additional Paid-In Capital	278	278	278	278	278	278
Retained Earnings	219.53	229.37	231.7	210.82	208.07	117.11
Comprehensive Income & Other	0.99	0.99	0.99	0.99	0.99	0.99
Total Common Equity	606.52	616.36	618.69	597.81	595.06	504.1
Shareholders' Equity	606.52	616.36	618.69	597.81	595.06	504.1
Total Liabilities & Equity	3,929	3,960	3,457	3,248	2,866	2,763

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,442	1,837	1,409	1,375	1,186	1,327
Net Cash (Debt)	-900.82	-1,073	-835.6	-729.76	-681.72	-685.4
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-8.34	-9.93	-7.74	-6.76	-6.31	-6.35
Filing Date Shares Outstanding	108	108	108	108	108	108
Total Common Shares Outstanding	108	108	108	108	108	108
Working Capital	278.29	279.79	241.39	193.14	206.77	79.3
Book Value Per Share	5.62	5.71	5.73	5.54	5.51	4.67
Tangible Book Value	534.29	542.04	540.2	515.06	508.18	355.04
Tangible Book Value Per Share	4.95	5.02	5.00	4.77	4.71	3.29
Buildings	298.92	298.92	298.21	298.21	269.2	329.71
Machinery	100.86	100.01	98.08	81.06	76.69	101.72

Data Source: S&P Global Market Intelligence Last updated: Sep 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 17, 2026

Data Sources Report a data error